The use of corticosteroids is linked to a higher risk for mortality in patients with acute exacerbations of idiopathic ...

Market regulator says excess expenses beyond the proposed limit must continue to be borne by depositories and unused amounts ...

At present, stock exchanges are permitted to use a maximum of 5 per cent of the interest or income generated from IPF ...

Novel targets aim to stop lung scarring—where current drugs only slow it—while improving tolerability and unlocking fibrosis ...

SEBI has proposed allowing depositories to use up to 5% of interest or income earned from Investor Protection Fund investments for administrative and statutory expenses. The proposal aims to align ...

In this episode of Denatured, you'll be hearing from Georg Vo Beiske, CEO of Tribune Therapeutics and Jonas Hallén, ...

MarketBeat's Top 5 Rated Small-Cap Stocks Trevi Therapeutics (NASDAQ:TRVI) outlined plans to advance Haduvio, its ...

What is Idiopathic Pulmonary Fibrosis (IPF)? IPF is a chronic, progressive, lung disease characterized by disabling shortness of breath, declining exercise capacity and extensive formation of scar ...

IPF has an insidious onset. It often presents with persistent dry cough associated with worsening breathlessness and progressive decline in one's exercise capacity. Hemoptysis (coughing up blood) is ...

Antifibrotic treatments for IPF, such as pirfenidone and nintedanib, are associated with significant side effects impacting quality of life. Despite side effects, patients perceive antifibrotics as ...

The proposal forms part of SEBI’s broader efforts to streamline investor protection mechanisms while ensuring adequate ...